Adam Crystal, President of R&D at Tango Therapeutics, Inc. (NASDAQ:TNGX), filed a Form 4 on November 4, 2026, disclosing transactions in common stock executed on November 2, 2026, under a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Crystal Adam exercised a stock option for 5,000 shares of common stock at an exercise price of $2.91 per share on November 2, 2026.
  • First sale: 3,900 shares were sold at a weighted average price of $22.2617 per share, with individual sale prices ranging from $21.83 to $22.8299 per share.
  • Second sale: 1,100 shares were sold at a weighted average price of $22.9882 per share, with individual sale prices ranging from $22.84 to $23.8399 per share.
  • Remaining direct holdings: Following all transactions, Adam directly beneficially owned 115,743 shares of common stock.
  • Derivative securities: Adam retained 313,090 stock options with an exercise price of $2.91 and an expiration date of February 3, 2035.
  • 10b5-1 plan: All transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2026, according to the filing.

Crystal Adam's November 2026 Option Exercise and Share Sales at Tango Therapeutics

According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 4, 2026, Crystal Adam, serving as President, R&D at Tango Therapeutics, Inc. (NASDAQ:TNGX), carried out three transactions on November 2, 2026. All transactions were conducted under a Rule 10b5-1 trading plan that the filing states was adopted on June 10, 2026.

The filing reports that Adam first exercised a stock option (transaction code M) covering 5,000 shares of common stock at an exercise price of $2.91 per share, bringing her directly held shares to 120,743. She then sold 3,900 shares (transaction code S) at a weighted average price of $22.2617 per share, with the filing noting individual prices ranged from $21.83 to $22.8299. A subsequent sale of 1,100 shares was executed at a weighted average price of $22.9882 per share, with individual prices ranging from $22.84 to $23.8399. After both sales, Adam's direct beneficial ownership in common stock stood at 115,743 shares, according to the filing.

In Table II, the filing discloses that the exercised option was originally granted with an exercise price of $2.91 and an expiration date of February 3, 2035. The filing states the option vests over a four-year period, with 25% vesting on January 1, 2026, and the remaining shares vesting in 36 equal monthly installments thereafter. Following the exercise, Adam's remaining beneficial ownership of these stock options is reported as 313,090.

What Was Disclosed

Crystal Adam, President, R&D of Tango Therapeutics, filed a Form 4 reporting a stock option exercise of 5,000 shares and two subsequent share sales totaling 5,000 shares on November 2, 2026, all executed under a pre-established 10b5-1 trading plan.